放射性标记生长抑素类似物用于肿瘤显像
本文综述放射性标记生长抑素类似物(SSA)用于肿瘤显像的发展与现状,指出68Ga-SSA PET/CT已取代111In-喷曲肽成为神经内分泌肿瘤(NET)显像主力,并用于分期、再分期、治疗计划及疗效评估;同时介绍18F与64Cu标记SSA及SSTR拮抗剂等新方向。
要点
- 68Ga-SSA PET/CT已取代111In-喷曲肽,成为NET显像主力,并纳入嗜铬细胞瘤-副神经节瘤、甲状腺髓样癌、脑膜瘤及肿瘤性骨软化症的显像指南。
- SSA PET/CT优势包括PET空间分辨率优于SPECT、可定量评估疾病活动与治疗反应、扫描时间更短及患者辐射暴露更少。
- 18F标记SSA、64Cu标记SSA及生长抑素拮抗剂是当前研究热点,后者以高亲和力与特异性提供高对比、低本底图像,有望用于诊疗一体化。
核心结论
- SSA PET/CT在NET显像中表现优于传统显像,已成为NET分期、原发灶检出(CUP-NETs)、再分期、治疗计划(联合FDG双示踪剂PET-CT)及疗效评估与随访的主要手段。
- SSA PET/CT已被纳入嗜铬细胞瘤-副神经节瘤、甲状腺髓样癌、脑膜瘤及肿瘤性骨软化症的显像指南。
- 18F标记SSA、64Cu标记SSA及生长抑素拮抗剂是当前研究热点,其中64Cu使延迟显像可行,对剂量学有意义;SSTR拮抗剂有望有效转化为诊疗一体化。
研究设计与样本
- 本文为综述,聚焦目前可用的SSA及其历史、不同SPECT/PET显像剂、SSTR拮抗剂、各显像示踪剂间比较及其在神经内分泌与非神经内分泌肿瘤中的应用。
主要发现
- 从首个放射性标记生长抑素类似物123I-Tyr-3-奥曲肽起步,所用放射性核素、配体及生长抑素衍生物均有显著发展。
- 111In-喷曲肽早期广泛用于NET显像,现已被68Ga-SSA PET-CT取代。
- SSA PET/CT优势包括:PET空间分辨率优于SPECT、PET可定量辅助疾病活动与治疗反应监测且精度更佳、扫描时间更短、患者辐射暴露更少。
- SSTR在非神经内分泌肿瘤中亦有文献报道,研究显示SSA PET/CT在神经母细胞瘤、鼻咽癌、前列腺癌(神经内分泌分化)及淋巴瘤中具有潜力。
关键数值与推荐
- SSA PET/CT适用于NET的分期、CUP-NETs原发灶检出、再分期、治疗计划(联合FDG的双示踪剂PET-CT)以及疗效评估与随访。
- SSA PET/CT已被纳入嗜铬细胞瘤-副神经节瘤、甲状腺髓样癌、脑膜瘤及肿瘤性骨软化症的显像指南。
临床怎么用
- SSA PET/CT已进入NET显像主流,用于分期、CUP-NETs原发灶检出、再分期、治疗计划(联合FDG双示踪剂PET-CT)及疗效评估与随访。
- SSA PET/CT亦被指南纳入嗜铬细胞瘤-副神经节瘤、甲状腺髓样癌、脑膜瘤及肿瘤性骨软化症的显像。
- 18F标记SSA、64Cu标记SSA及生长抑素拮抗剂为当前研究方向,其中64Cu使延迟显像可行,对剂量学有意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatostatin receptors (SSTR) are expressed by many tumours especially those related to neuro-endocrine origin and molecular functional imaging of SSTR expression using radiolabelled somatostatin analogs have revolutionized imaging of patients with these group of malignancies. Coming a long way from the first radiolabelled somatostatin analog 123I-Tyr-3-octreotide, there has been significant developments in terms of radionuclides used, the ligands and somatostatin derivatives. 111In-Pentetreotide extensively employed for imaging NETs at the beginning has now been replaced by 68Ga-SSA based PET-CT. SSA-PET/CT performs superior to conventional imaging modalities and has evolved in the mainframe for NET imaging. The advantages were multiple: (i) superior spatial resolution of PET versus SPECT, (ii) quantitative capabilities of PET aiding in disease activity and treatment response monitoring with better precision, (iii) shorter scan time and (iv) less patient exposure to radiation. The modality is indicated for staging, detecting the primary in CUP-NETs, restaging, treatment planning (along with FDG: the concept of dual-tracer PET-CT) as well as treatment response evaluation and follow-up of NETs. SSA PET/CT has also been incorporated in the guidelines for imaging of Pheochromocytoma-Paraganglioma, Medullary carcinoma thyroid, Meningioma and Tumor induced osteomalacia. At present, there is rising interest on (a) 18F-labelled SSA, (b) 64Cu-labelled SSA, and (c) somatostatin antagonists. 18F offers excellent imaging properties, 64Cu makes delayed imaging feasible which has implications in dosimetry and SSTR antagonists bind with the SST receptors with high affinity and specificity, providing high contrast images with less background, which can be translated to theranostics effectively. SSTR have been demonstrated in non-neuroendocrine tumours as well in the peer-reviewed literature, with studies demonstrating the potential of SSA PET/CT in Neuroblastoma, Nasopharyngeal carcinoma, carcinoma prostate (neuroendocrine differentiation) and lymphoma. This review will focus on the currently available SSAs and their history, different SPECT/PET agents, SSTR antagonists, comparison between the various imaging tracers, and their utility in both neuroendocrine and non-neuroendocrine tumors.
引用
- Nazar AK, Basu S. Radiolabeled Somatostatin Analogs for Cancer Imaging. Semin Nucl Med. 2024. PMID: 39122608. doi:10.1053/j.semnuclmed.2024.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。